Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin and thereby preserving human immune cells by protecting against destruction of host cells...
- Mechanism
- Curator reviewed · 6 references
Staphylococcus aureus alpha-toxin is a virulence factor secreted by methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA), with S. aureus being a leading cause of hospital-acquired lower respiratory tract infections and bloodstream, skin, soft tissue, and surgical site infections. Tosatoxumab acts as a monoclonal antibody against infections caused by MRSA and MSSA by targeting the S. aureus alpha-toxin, with its mode of action being independent of the antibiotic resistance profile of S. aureus.
- Code names
- AR-301 · KBSA-301
Resolves to
What you can answer from here — as of April 23, 2025
Which companies are running trials of Tosatoxumab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account